Literature DB >> 9863636

The influence of lobeline on nucleus accumbens dopamine and locomotor responses to nicotine in nicotine-pretreated rats.

M E Benwell1, D J Balfour.   

Abstract

In vivo brain microdialysis was used to investigate the influence of lobeline on dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) overflow in the core of the nucleus accumbens of freely-moving rats pretreated with nicotine (0.4 mg x kg(-1), s.c., once per day for 5 days). Locomotion was also recorded. Lobeline, at doses of 0.7, 4.0 and 10.0 mg x kg(-1), i.p., failed to elicit any significant changes in extracellular dopamine or dihydroxyphenylacetic acid levels during the 60 min following its administration and did not stimulate locomotor. The dopamine responses to nicotine (0.4 mg x kg(-1), s.c.), were abolished (P<0.01) if the nicotine challenge was administered 10 min but not 60 min, after lobeline doses of 4.0 and 10.0 mg kg(-1), i.p., but were unaffected following lobeline at the lowest dose tested (0.7 mg x kg(-1), i.p.) at either time. The increase in locomotor activity was significantly attenuated (P<0.01), to a similar extent, when the nicotine was injected 10 min, but not 60 min, after all three doses of lobeline (0.7, 4.0 and 10.0 mg kg(-1), i.p.) when compared with the saline-treated rats. The results suggest that lobeline is a short-acting antagonist of the nicotinic AChRs which mediate the effects of nicotine on mesolimbic dopamine activity and locomotor stimulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863636      PMCID: PMC1565682          DOI: 10.1038/sj.bjp.0702161

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  The effects of lobeline and naltrexone on methamphetamine-induced place preference and striatal dopamine and serotonin levels in adolescent rats with a history of maternal separation.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-04       Impact factor: 3.584

2.  Lobeline attenuates methamphetamine-induced stereotypy in adolescent mice.

Authors:  Tomohiro Tatsuta; Nobue Kitanaka; Junichi Kitanaka; Yoshio Morita; Motohiko Takemura
Journal:  Neurochem Res       Date:  2006-10-20       Impact factor: 3.996

3.  The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.

Authors:  Joshua S Beckmann; Kiran B Siripurapu; Justin R Nickell; David B Horton; Emily D Denehy; Ashish Vartak; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  J Pharmacol Exp Ther       Date:  2010-08-30       Impact factor: 4.030

4.  Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.

Authors:  Steven B Harrod; M Lee Van Horn
Journal:  Pharmacol Biochem Behav       Date:  2009-09-17       Impact factor: 3.533

5.  Local perfusion of nicotine differentially modulates somatodendritic dopamine release in the rat ventral tegmental area after nicotine preexposure.

Authors:  S Rahman; J Zhang; W A Corrigall
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

6.  Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.

Authors:  Andrew C Meyer; Nichole M Neugebauer; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  J Neurochem       Date:  2013-08-20       Impact factor: 5.372

7.  Lobelane decreases methamphetamine self-administration in rats.

Authors:  Nichole M Neugebauer; Steven B Harrod; Dustin J Stairs; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Eur J Pharmacol       Date:  2007-06-13       Impact factor: 4.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.